LMNA and Hutchinson-Gilford progeria syndrome: These findings should be considered in the future design of gene‐editing therapies aimed at reducing progerin expression in HGPS patients (Beyret et al., 2019; Koblan et al., 2021; Santiago‐Fernandez et al., 2019; Whisenant et al., 2022), as these therapies may be safer and more efficient if targeted to specific cell types.